RenovoRx (RNXT) Q1 2026 earnings review
Commercial Ramp Accelerates, But Profitability Remains Distant
RenovoRx delivered a record Q1 with revenue hitting $563K (up 136% sequentially). Early adoption of the RenovoCath device is proving unit economics, with gross margins leaping to 85.1%. However, the transition to a commercial-stage company is expensive. SG&A expenses surged 73% YoY to $2.7M, widening the net loss to $3.5M. While a recent $10M capital raise fortifies the balance sheet, management's claim of a cash runway stretching into late 2027 hinges on either massive near-term sales acceleration or severe post-clinical cost reductions.
🐂 Bull Case
Active commercial cancer centers doubled from 8 at the end of 2025 to 16 today, with an additional 32 centers in the evaluation pipeline. Management noted meaningful organic repeat utilization.
The Phase III TIGeR-PaC trial is nearing its end. With 106 of 114 required patients randomized, enrollment is firmly on track to close by June 2026, removing a major overhang.
🐻 Bear Case
Despite a record top line, Q1 net loss expanded to $3.5M. The company spent $2.7M on SG&A to generate $563K in sales—a ratio that must drastically improve to justify the current valuation.
Management claims $12.4M in cash will last into H2 2027. At a $3.5M quarterly burn rate, the math requires either steep expenditure cuts post-trial enrollment or near-flawless commercial execution to bridge the gap.
⚖️ Verdict: ⚪
Neutral. The commercial traction and 85% gross margins are genuinely impressive for this early stage. However, the rapidly rising SG&A costs and the long wait for 2027 Phase III data mean dilution risk remains a near-term reality.
Key Themes
Accelerating Center Activations Driving Sales
RenovoRx is proving its commercial hypothesis. Active centers grew from 5 in early 2025, to 8 at year-end, to 16 today. Furthermore, up to 15 trial centers are expected to transition to commercial accounts in H2 2026 once the TIGeR-PaC trial enrollment concludes. This provides a highly visible pipeline for continued revenue growth.
Gross Margins Validate Unit Economics
Accelerating scale is drastically improving the bottom line of the device itself. Gross margin expanded from 52.3% in 25Q1 to 85.1% in 26Q1. This confirms that the standalone RenovoCath device has highly attractive unit economics, provided the company can control overhead costs.
The Heavy Cost of Commercialization
While revenue is growing, the cost to acquire it is growing faster. SG&A expenses surged 73% YoY to $2.7M, reflecting the necessary but painful expansion of commercial infrastructure. The pivot from an R&D-heavy to an SG&A-heavy profile is underway, putting pressure on near-term cash flow.
TIGeR-PaC Trial Approaches Checkered Flag
The Phase III TIGeR-PaC trial is approaching a pivotal turning point. The company has randomized 106 of 114 patients and observed 74 of the 86 deaths required for the final analysis. Closure of enrollment is explicitly targeted for June 2026. However, investors will still have to wait until mid-to-late 2027 for the final data readout.
Runway Guidance Contradicts Burn Rate
Management stated that $12.4M in cash is sufficient to fund operations into at least the second half of 2027. However, with a Q1 net loss of $3.5M (an annualized burn of $14M), this runway is mathematically impossible without either a massive inflection in high-margin sales or severe expense reductions following clinical enrollment. We flag this as a critical monitoring point.
Other KPIs
Reversing downward. R&D fell from $1.6M a year ago, primarily driven by higher receipts received from the TIGeR-PaC clinical trial. We expect this line item to decline further in H2 2026 after trial enrollment officially closes.
Strengthened by a March 2026 private placement that generated $10M in gross proceeds. This is a vital lifeline for a company burning over $3M per quarter in its initial commercial scale-up.
Guidance
Accelerating. Management reiterated its full-year guidance. Compared to FY25's $1.1M in revenue, this implies roughly 170% to 260% YoY growth. With $563K achieved in Q1, the company needs to average about $800K to $1.1M per quarter for the rest of the year to meet this target.
Stable. The company remains on track to close enrollment by June, hitting a previously stated mid-2026 target.
Accelerating. Improving from the 16 centers active today, requiring the onboarding of roughly 6-7 centers per quarter for the remainder of the year. The expected transition of 15 trial centers to commercial use in H2 2026 heavily underpins this target.
Key Questions
Bridging the Cash Runway Gap
Your current cash balance is $12.4M, and Q1 net loss was $3.5M. Can you bridge the math on how this gets you into the second half of 2027? Are you modeling severe R&D cuts post-enrollment, or are you projecting a massive inflection in cash-generating sales?
SG&A Leverage
SG&A expanded to $2.7M this quarter to support commercialization. Should investors expect SG&A to stabilize at this run rate, or will it continue to scale linearly with new center activations?
Trial Center Conversion
You anticipate transitioning up to 15 clinical trial centers to commercial accounts in H2 2026. Have these centers already navigated their Value Analysis Committees (VAC), or is there still an administrative hurdle before they can place commercial orders?